- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04298489
Drug Sensitivity Screening for Gastrointestinal Cancer
Personalized Drug Sensitivity Test for Late Stage, Potentially Operable Gastrointestinal Cancer Using Patient Derived Primary Cell Culture
Explore the clinical feasibility of using primary cell culture system to guide gastrointestinal cancer chemotherapy, and establish the correlation between ex vivo drug sensitivity and patient clinical response.
Study objectives: Personalized drug sensitivity test for late stage,potentially operable gastrointestinal cancer using patient derived primary cell culture.
Explore the clinical feasibility of using primary cell culture system to guide gastrointestinal cancer chemotherapy, and establish the correlation between ex vivo drug sensitivity and patient clinical response.
The study will collect primary tumor tissues from stage III/IV gastrointestinal cancer patients who underwent emergency surgeries, and then establish the primary tumor cell library for ex vivo chemotherapy drug sensitivity test in order to:
- Compare the ex vivo Maximal Inhibition Index(MI) and Drug Sensitivity Index (DSI) with patient's Overall Response Rate (ORR)
- Provide research support for future clinical treatment.
This ex vivo method applies to single or combination drug regimen, and does not require prior knowledge of the specific mechanism for individual patient's drug sensitivity. Previous research as well as literature studies support the close relationship between ex vivo drug sensitivity and in vivo drug response.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The patient underwent surgery to remove tumor and agreed to take out the abdominal tumor specimens for research. A section of each sample was removed for the generation of PDX models as described early.The rest of the tumor cells were expanded using ex vivo drug sensitivity assay.
The drugs used in the study were 5-fluorouracil, Oxaliplatin, and irinotecan at C0 = 10 mM, 2.5 mM and 0.02 mM, respectively. They were applied either as single agents or in combinations of 5-fluorouracil and Oxaliplatin, 5-fluorouracil and irinotecan, or all three agents, or others. After 7 days of treatment, the tumor cells were stained with EdU, Hoechst and EpCAM with the Cell Quantitative Detection Kit. Images were acquired with an automated microscopic image-scanning system and analyzed with the built-in software.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yingjie Li, M.D.
- Phone Number: +86 13520186618
- Email: liyingjiedr@sina.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Recruiting
- Beijing Cancer Hospital
-
Sub-Investigator:
- Yingjie Li, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients between 18 and 70 years old, male or female;
- Voluntary patient consent;
- Treatment-naïve, stage III/IV gastrointestinal cancer patients with pathology confirmation;
- According clinical researcher, patient has operable tumor lesion, and tumor tissue can be obtained through surgical removal;
- Good tolerability to standard chemotherapy regimen;
- ECOG status <3;
- Estimated survival time no less than 6 months;
- Patient has at least one measurable disease lesion (according to RECIST1.1).
Exclusion Criteria:
- Patient has received any prior anti-cancer treatment;
- Participated in any other clinical study within 6 months;
- Women currently breast feeding or pregnant;
- Severe liver or kidney function impairment (Live function: TBIL ≤1.5×ULN,ALT & AST≤2.5×ULN);
- Patients with liver metastasis ≤5.0×ULN;Kidney function:Cr ≤1.5×ULN and creatinine clearance rate≥ 50 mL/min (according to the Cockcroft-Gault formula);
- Patients with cognitive impairment, psychological disease, or poor compliance;
- Allergic to known chemotherapy ingredients;
- Other factors researchers deemed not suitable for study participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: stage III/IV gastrointestinal cancer patients
The study group (Personalized drug sensitivity test) was treated according to the physician's opinion.
Tumor tissues are obtained during the surgery or via biopsy with informed consent, for the purpose of ex vivo assay.
|
The patients underwent surgery to remove tumor and took out tumor specimens for research. The tumor cells were expanded ex vivo drug sensitivity assay. The drugs used in the study were 5-fluorouracil, Oxaliplatin, and irinotecan at C0 = 10 mM, 2.5 mM and 0.02 mM, respectively. They were applied either as single agents or in combinations of 5-fluorouracil and Oxaliplatin, 5-fluorouracil and irinotecan, or all three agents, or others. After 7 days of treatment, the tumor cells were stained with EdU, Hoechst and EpCAM with the Cell Quantitative Detection Kit. Images were acquired with an automated microscopic image-scanning system and analyzed with the built-in software. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ex vivo Maximal Inhibition Index (MI)
Time Frame: 1 month after the tissue acquisition
|
The effectiveness of each therapeutic regimen was evaluated and quantified using the formula: Maximum Inhibition (MI)=N0/Nd, where N0 and Nd denotes the number of EpCAM+ EdU+ epithelial cells in the wells of control or withthe drug at concentration C0, respectively.
|
1 month after the tissue acquisition
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate(DCR)after chemotherapy
Time Frame: 3 months after chemotherapy
|
Disease Control Rate(DCR)after chemotherapy.
|
3 months after chemotherapy
|
Progression free survival (PFS) after chemotherapy
Time Frame: 1 year after chemotherapy
|
Progression free survival (PFS) after chemotherapy
|
1 year after chemotherapy
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PKUCH-M01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Cancer Metastatic
-
Hoffmann-La RocheFoundation MedicineRecruitingMetastatic Lung Cancer | Metastatic Gastrointestinal CancerSpain, France, Italy, Germany, Netherlands
-
Centre Hospitalier Universitaire de BesanconNational Cancer Institute, FranceCompletedGastrointestinal Metastatic CancerFrance
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC Utrecht; University of Cambridge; IRCCS Fondazione Stella MarisRecruitingGastrointestinal Cancer MetastaticNetherlands, United Kingdom, Italy
-
Boehringer IngelheimCompletedGastrointestinal Cancer, MetastaticBelgium, United States, France, Japan, China
-
Five Prime Therapeutics, Inc.CompletedGastric Cancer | Gastrointestinal Cancer | Gastrointestinal Cancer MetastaticUnited States
-
Royal Marsden NHS Foundation TrustRecruitingMetastatic Gastric Cancer | Metastatic Esophageal CancerUnited Kingdom
-
Dana-Farber Cancer InstituteCompletedPhysical Activity | Metastatic Gastrointestinal CancerUnited States
-
Erasmus Medical CenterSanofiWithdrawnMetastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerNetherlands
-
University of California, San FranciscoNot yet recruitingGastrointestinal Cancers | Gastrointestinal Cancer MetastaticUnited States
-
University of UtahNot yet recruitingMetastatic Colon Cancer | Metastatic Rectum CancerUnited States
Clinical Trials on Personalized drug sensitivity test
-
Case Comprehensive Cancer CenterFlorida International University; Community Foundation of BrowardRecruitingRelapsed Cancer | Refractory CancerUnited States
-
Affiliated Hospital of Jiangnan UniversityRecruitingLung Cancer | OrganoidChina
-
Zhejiang Cancer HospitalCompletedPathological Conditions, Signs and SymptomsChina
-
Ruijin HospitalChongqing Kingbiotech Co.,LtdNot yet recruitingAdvanced Pancreatic Neuroendocrine TumorChina
-
The Children's Hospital of Zhejiang University...College of Pharmaceutical Science at Zhejiang UniversityRecruitingAcute Myeloid Leukemia in ChildrenChina
-
Center of Implantology, Oral and Maxillofacial...CompletedPeri-Implantitis | Peri-implant Mucositis | Sensitivity | Peri-Implantational LossSpain
-
Peking Union Medical College HospitalRecruitingColo-rectal CancerChina
-
Hadassah Medical OrganizationUnknownCoronary Stent RestenosisIsrael
-
Changhai HospitalRecruiting
-
Champions OncologyMount Sinai Hospital, CanadaTerminated